{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:54:36Z","timestamp":1791284076265,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2020,1]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n \n Psoriasis is a chronic inflammatory skin disease associated with quality of life (QoL) impairment.\n BRIDGE<\/jats:styled-content>\n was a randomized, double\u2010blind, phase\n III<\/jats:styled-content>\n study comparing the efficacy and safety of dimethylfumarate (\n DMF<\/jats:styled-content>\n ) with a fixed combination of fumaric acid esters (\n FAE<\/jats:styled-content>\n ) or placebo for the treatment of moderate\u2010to\u2010severe psoriasis.\n <\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n \n This post hoc analysis investigated treatment effect on QoL overall and by patient subgroups categorized by disease severity. Week 8 efficacy responses were also investigated as possible predictors of Week 16 Dermatology Life Quality Index (\n DLQI<\/jats:styled-content>\n ) outcomes.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Patients were randomized to receive a maximum daily dose of 720\u00a0mg of\n DMF<\/jats:styled-content>\n ,\n FAE<\/jats:styled-content>\n (gradual up\u2010titration) or placebo for 16\u00a0weeks. Psoriasis Area Severity Index, Body Surface Area, Physician's Global Assessment and\n DLQI<\/jats:styled-content>\n were assessed at baseline, Weeks 8 and 16.\n DLQI<\/jats:styled-content>\n 0\u20101 indicated \u2018no effect on patient life\u2019. Associations between baseline severity, Week 16\n DLQI<\/jats:styled-content>\n and Week 8 efficacy (as observed cases) were also examined.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n At baseline, 671 patients were included in the full analysis set (267 randomized to\n DMF<\/jats:styled-content>\n , 273 to\n FAE<\/jats:styled-content>\n and 131 to placebo).\n DMF<\/jats:styled-content>\n was superior to placebo (\n P<\/jats:italic>\n \u00a0<\u00a00.001) and not significantly different to\n FAE<\/jats:styled-content>\n regarding Week 16\n DLQI<\/jats:styled-content>\n outcomes (\n P<\/jats:italic>\n \u00a0>\u00a00.05). Baseline disease severity did not impact\n DLQI<\/jats:styled-content>\n outcomes at Week 16. In\n DMF<\/jats:styled-content>\n \u2010 and\n FAE<\/jats:styled-content>\n \u2010treated patients, Week 8\n PASI<\/jats:styled-content>\n 50\/75 responders reported better\n DLQI<\/jats:styled-content>\n responses at Week 16 vs non\u2010responders (\n P\u00a0<\/jats:italic>\n <\u00a00.05). Week 8\n PASI<\/jats:styled-content>\n \u00a0\u2264\u00a03 and\/or\n PGA<\/jats:styled-content>\n 0\u20101 responders were also more likely to report\n DLQI<\/jats:styled-content>\n 0\u20101 at Week 16 vs non\u2010responders (\n P\u00a0<\/jats:italic>\n <\u00a00.05).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Dimethylfumarate significantly improved\n DLQI<\/jats:styled-content>\n outcomes vs. placebo and was not affected by baseline disease severity. Efficacy responses (\n PASI<\/jats:styled-content>\n 50\/75,\n PASI<\/jats:styled-content>\n \u22643 and\n PGA<\/jats:styled-content>\n 0\u20101) as early as Week 8 were predictive of QoL outcomes at Week 16 in\n DMF<\/jats:styled-content>\n \u2010 and\n FAE<\/jats:styled-content>\n \u2010treated patients.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/jdv.15922","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T13:59:10Z","timestamp":1567087150000},"page":"119-126","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Quality of life outcomes in adults with moderate\u2010to\u2010severe plaque psoriasis treated with dimethylfumarate (\n DMF<\/scp>\n ): a post hoc analysis of the\n BRIDGE<\/scp>\n study"],"prefix":"10.1111","volume":"34","author":[{"given":"P.C.M.","family":"van de Kerkhof","sequence":"first","affiliation":[{"name":"Department of Dermatology Radboud University Medical Centre Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Loewe","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9539-0712","authenticated-orcid":false,"given":"U.","family":"Mrowietz","sequence":"additional","affiliation":[{"name":"Psoriasis\u2010Centre Department of Dermatology University Medical Centre Schleswig\u2010Holstein Campus Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Falques","sequence":"additional","affiliation":[{"name":"Almirall R&D Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Pau\u2010Charles","sequence":"additional","affiliation":[{"name":"Almirall R&D Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-6342","authenticated-orcid":false,"given":"J.C.","family":"Szepietowski","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology Wroclaw Medical University Wroc\u0142aw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1087-0024.2003.09102.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.12.1537"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.09.022"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-35"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20153038"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.055"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13354"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.027"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15218"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14947"},{"key":"e_1_2_6_13_1","unstructured":"European Medicines Agency (EMA).EPAR summary for the public: Skilarence dimethyl fumarate. URLhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/002157\/WC500231110.pdf(last accessed: 2017 July 2018)."},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031237"},{"key":"e_1_2_6_15_1","first-page":"S14","article-title":"The skin in psoriasis: assessment and challenges","volume":"33","author":"Oji V","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)70172-5"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.5541510.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-008-0885-7"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000113150"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05378.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.04.014"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.45101"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12106"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000365390"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"e_1_2_6_26_1","unstructured":"National Institute of Clinical Excellence (NICE).Clinical Guideline (CG153). Psoriasis: assessment and management.2017. URLhttps:\/\/www.nice.org.uk\/guidance\/cg153\/chapter\/1-guidance(last accessed October 2018)."},{"key":"e_1_2_6_27_1","first-page":"1086","article-title":"Time to raise the bar to psoriasis area severity index 90 and 100","volume":"14","author":"Manalo IF","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1395794"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15216"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.001"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-016-1470-2"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.10.547"},{"key":"e_1_2_6_33_1","unstructured":"DaudenE CarrascosaJM De la CuevaP Pau\u2010CharlesI Fernandez\u2010SorianoFJ.Efficacy of dimethylfumarate after 24 weeks of treatment according to clinical practice in patients with moderate\u2010to\u2010severe psoriasis. National Congress of Psoriasis: 4th meeting of the Psoriasis Group (GPs) of the AEDV;2019; Madrid Spain."},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13098"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.15922","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.15922","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.15922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:30:47Z","timestamp":1791282647000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.15922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1111\/jdv.15922"],"URL":"https:\/\/doi.org\/10.1111\/jdv.15922","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,17]]},"assertion":[{"value":"2019-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}